Since no therapy has yet been developed with adiponectin, being a novel hormone, we suggest that the osmotin could be used as a drug design template in therapeutic strategies for the treatment of obesity-related insulin resistance. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.